CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis.

Aim: To confirm previous conclusions on () CNCM I-3856 for irritable bowel syndrome (IBS) management.

Methods: An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of CNCM I-3856 supplementation on gastrointestinal (GI) symptoms in IBS subjects. A total of 579 IBS subjects were included.